Last reviewed · How we verify

NCT06803394: K-HEARS

Hearing Health Equity Through Accessible Research and Solutions for Korean Americans

ENROLLING BY INVITATION NA Last updated 12 March 2026
What this trial tests

NA trial testing K-HEARS Intervention in Age-related Hearing Impairment in 800 participants. Enrolling by invitation.

Timeline
9 February 2025
Primary endpoint
1 February 2028
30 September 2028

Quick facts

Lead sponsorJohns Hopkins University
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment800
Start date9 February 2025
Primary completion1 February 2028
Estimated completion30 September 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

18 and older, any sex, with Age-related Hearing Impairment or Personal Communication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to test the effect of a community-delivered, affordable, and accessible hearing care intervention on improving communication function and health-related quality of life among older Korean Americans (KA) and the older Korean American's care partners that integrates a low-cost over-the-counter amplification device and hearing rehabilitation in comparison to a 6-month delayed treatment group through a cluster randomized controlled study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of K-HEARS Intervention

Trials testing the same drug.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06803394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing